SEC Company Response from TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956) (TENX) — Dec 7, 2018

TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)
Date: Dec. 7, 2018 · CIK: 0000034956 · Accession: 0001654954-18-013705

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-228212

Date

Dec. 7, 2018

Author

Managing Director

Form

CORRESP

Company

TENAX THERAPEUTICS, INC. (TENX) (CIK 0000034956)

Letter

Blueprint

Ladenburg Thalmann & Co. Inc.

Vanderbilt Beach Road, Suite 200

Naples, Florida 34108

December 7, 2018

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, DC 20549

Re:

TENAX THERAPEUTICS, INC.

Registration Statement on Form S-1 (Registration No. 333-228212)

Concurrence in Acceleration Request

Ladies and Gentlemen:

Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the above-referenced offering, hereby concurs in the request by Tenax Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 12:30 p.m. (Eastern Time), or as soon as practicable thereafter, on December 7, 2018, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very
truly yours,
LADENBURG
THALMANN & CO. INC.

Show Raw Text

CORRESP
1
filename1.htm

Blueprint

Ladenburg Thalmann & Co. Inc.

999
Vanderbilt Beach Road, Suite 200

Naples,
Florida 34108

December
7, 2018

VIA FACSIMILE AND EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

Washington,
DC 20549

Re:

TENAX THERAPEUTICS, INC.

 Registration
Statement on Form S-1 (Registration No. 333-228212)

Concurrence
in Acceleration Request

Ladies
and Gentlemen:

Ladenburg Thalmann
& Co. Inc. (“Ladenburg”), as representative of the
underwriters for the above-referenced offering, hereby concurs in
the request by Tenax Therapeutics,
Inc. that the effective date of the above-referenced
registration statement be accelerated to 12:30 p.m. (Eastern Time),
or as soon as practicable thereafter, on December 7, 2018, pursuant
to Rule 461 under the Securities Act. Ladenburg affirms that it is
aware of its obligations under the Securities Act in connection
with this offering.

Very
truly yours,

LADENBURG
THALMANN & CO. INC.

By:

/s/ Nicholas
Stergis

Name:
Nicholas Stergis

Title:
Managing Director

SecProbe.io